FDA approved AstraZeneca's Imfinzi regimen for muscle-invasive bladder cancer, while the EU backed Calquence combo for untreated mantle cell lymphoma.

The Food and Drug Administration (FDA) has approved Imfinzi ® (durvalumab), in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent Imfinzi as adjuvant ...

AstraZeneca has secured another expansion of its Imfinzi for use in cancer patients before and after surgery. | Imfinzi is ...

AstraZenecas drug Imfinzi (NASDAQ: AZN) has received U.S. approval to treat adult patients with muscle-invasive bladder ...

Imfinzi in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by Imfinzi as adjuvant monotherapy ...

BioNTech has shown why it made small cell lung cancer (SCLC) a priority for its PD-L1xVEGF-A bispecific. | BioNTech has shown ...

The FDA approved neoadjuvant Imfinzi, gemcitabine and cisplatin, followed by adjuvant Imfinzi after radical cystectomy in ...

The MATTERHORN trial showed Imfinzi plus chemotherapy significantly improves event-free survival in resectable gastric and GEJ cancers. Imfinzi regimen demonstrated a strong trend favoring overall ...

Imfinzi plus chemotherapy significantly improved event-free survival in resectable Stage II-IVA gastric and GEJ cancer patients. A strong trend in overall survival benefit was observed ...

AstraZeneca (AZN), a prominent player in the pharmaceuticals industry with a market capitalization of $239.77 billion, announced its IMFINZI (durvalumab) treatment has shown a statistically ...

A strong trend was observed for the secondary endpoint of overall survival (OS) in favor of the Imfinzi-based regimen. The trial will follow OS, which will be formally assessed at the final analysis.